Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

Neuro-Oncology

Volumn 10, Issue 1, 2008, Pages 10-18

  Mitchell, Duane A ^a   Xie, Weihua ^a   Schmittling, Robert ^a   Learn, Chris ^a   Friedman, Allan ^a   McLendon, Roger E ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; Glioma; Human cytomegalovirus; Viruses

Indexed keywords

VIRUS DNA; VIRUS PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOTOMY; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; TUMOR CELL; VIREMIA; VIRUS DETECTION; VIRUS REACTIVATION;

BRAIN NEOPLASMS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; VIREMIA;

EID: 39149136486     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2007-035     Document Type: Article

References (50)

1. Michelson-Fiske S. Human cytomegalovirus: a review of developments between 1970 and 1976. Part II. Experimental developments. Biomedicine. 1977;26:86-97.
2. Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J Infect. 2002;44:78-83.
3. Rafferty KA Jr. Herpes viruses and cancer. Sci Am. 1973;229:26-33.
4. Kadow JF, Regueiro-Ren A, Weinheimer SP. The role of viruses in human cancer development and antiviral approaches for intervention. Curr Opin Investig Drugs. 2002;3:1574-1579.
5. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347-3350.
6. Harkins L, Volk AL, Samanta I, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002;360:1557-1563.
7. Samanta M, Harkins L, Klem K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170:998-1002.
8. Zafiropoulos A, Tsentelierou E, Billirik, Spandidos DA. Human herpes viruses in non-melanoma skin cancers. Cancer Lett. 2003;198:77-81.
9. Roche JK, Cheung KS, Boldogh I, Huang ES, Lang DJ. Cytomegalovirus: detection in human colonic and circulating mononuclear cells in association with gastrointestinal disease. Int J Cancer. 1981;27:659-667
10. Hart H, Neill WA, Norval M. Lack of association of cytomegalovirus with adenocarcinoma of the colon. Gut. 1982;23:21-30.
11. Grail A, Norval M. Elution of cytomegalovirus antibodies from adenocarcinoma of the colon. Gut. 1985;26:1053-1058.
12. Lau SK, Chen YY, Chen WG, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838-843.
13. Sabatier J, Uro-Coste E, Pommepuy I, et al. Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer. 2005;92:747-750.
14. Poltermann S, Schlehofer B, Steindorf K, et al. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90-99.
15. Cinatl J Jr, Kotchetkov R, Scholz M, et al. Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am J Pathol. 1999;155:285-292.
16. Basta S, Bennink JR. A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol. 2003;16:231-242.
17. Cinatl J Jr, Vogel JU, Kotchetkov R, et al. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol Rev. 2004;28:59-77.
18. Hoever G, Vogel JU, Lukashenko P, et al. Impact of persistent cytomegalovirus infection on human neuroblastoma cell gene expression. Biochem Biophys Res Commun. 2005;326:395-401.
19. Bego MG, St Jeor S. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp Hematol. 2006;34:555-570.
20. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259:219-246.
21. Kuhn JE, Wendland T, Eggers HJ, et al. Quantitation of human cytomegalovirus genomes in the brain of AIDS patients. J Med Virol. 1995;47:70-82.
22. Rapp F, Li JL. Demonstration of the oncogenic potential of herpes simplex viruses and human cytomegalovirus. Cold Spring Harb Symp Quant Biol. 1975;39:747-763.
23. Geder KM, Lausch R, O'Neill F, Rapp F. Oncogenic transformation of human embryo lung cells by human cytomegalovirus. Science. 1976;192:1134-1137
24. Geder L, Rapp F. Evidence for nuclear antigens in cytomegalovirus- transformed human cells. Nature. 1977;265:184-186.
25. Buhren J, Christoph AH, Buslei R, et al. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: evidence for a medulloblastoma subtype derived from the external granule cell layer. J Neuropathol Exp Neurol. 2000;59:229-240.
26. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A. 1998;95:3937-3942.
27. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J Virol. 1999;73:4806-4812.
28. Lagasse N, Dhooge I, Govaert P. Congenital CMV-infection and hearing loss. Acta Otorhinolaryngol Belg. 2000;54:431-436.
29. Cohrs RJ, Gilden DH. Human herpesvirus latency. Brain Pathol. 2001;11:465-474.
30. Reeves MB, Coleman H, Chadderton J, et al. Vascular endothelial and smooth muscle cells are unlikely to be major sites of latency of human cytomegalovirus in vivo. J Gen Virol. 2004;85:3337-3341.
31. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10(a):133-146.
32. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100:216-232.
33. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294-302.
34. Dalessandro L, Bottaro E. Reactivation of CMV retinitis after treatment with subtenon corticosteroids for immune recovery uveitis in a patient with AIDS. Scand J Infect Dis. 2002;34:780-782.
35. Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus. 2006;20:E3.
36. Preiser W, Bräuninger S, Schwerdtfeger R, et al. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol. 2001;20:59-70.
37. Zekri AR, Mohamed WS, Samra MA, et al. Risk factors for cytomegalovirus, hepatitis B, and C virus reactivation after bone marrow transplantation. Transpl Immunol. 2004;13:305-311.
38. van Den Pol AN, Mocarski E, Saederup N, Vieira J, Meier TJ. Cytomegalovirus cell tropism, replication, and gene transfer in brain. J Neurosci. 1999;19:10948-10965.
39. van Den Pol AN, Vieira J, Spencer DD, Santarelli JG. Mouse cytomegalovirus in developing brain tissue: analysis of 11 species with GFP-expressing recombinant virus. J Comp Neurol. 2000;427:559-580.
40. Lecointe D, Dugas N, Leclerc P, Hery C, Delfraissy JF, Tardieu M. Human cytomegalovirus infection reduces surface CCR5 expression in human microglial cells, astrocytes, and monocyte-derived macrophages. Microbes Infect. 2002;4:1401-1408.
41. Reis B, Bogner E, Reschke M, et al. Stable constitutive expression of glycoprotein B (gpUL55) of human cytomegalovirus in permissive astrocytoma cells. J Gen Virol. 1993;74:1371-1379.
42. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.
43. Wang X, Huong SM, Chin ML, Raab-Traub N, Huang ES. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature. 2003;424:456-461.
44. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84:6899-6903.
45. Humphrey PA, Wong AJ, Vogelstein B, et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 1988;48:2231-2238.
46. Liu TF, Tatter SB, Willingham MC, et al. Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther. 2003;2:783-787.
47. Hengel H, Brune W, Koszinowski UH. Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol. 1998;6:190-197.
48. Reddehase MJ. The immunogenicity of human and murine cytomegaloviruses. Curr Opin Immunol. 2000;12:390-396.
49. Kossmann T, Morganti-Kossmann MC, Orenstein JM, et al. Cytomegalovirus production by infected astrocytes correlates with transforming growth factor-beta release. J Infect Dis. 2003;187:534-541.
50. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 1995;13:545-586.